Abstract
Background:Inhibition of interleukin-1 (IL-1) represents a promising treatment option in adult-onset Still’s disease (AOSD). Canakinumab is approved for treatment of systemic juvenile idiopathic arthritis and has a marked impact on...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have